InsidersTradesSigma
Follow the Biohaven Pharmaceutical Holding Co Ltd. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Biohaven Pharmaceutical Holding Co Ltd. has recorded 46 public disclosures. Market capitalisation: €2.3bn. The latest transaction was filed on 3 October 2022 (Disposition). Among the most active insiders: Clark George C.. All data is accessible without an account.
46
Insider Decl.
n/a
Thresholds
€6m
2 ops.
Buy Volume
€879m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Biohaven Pharmaceutical Holding Co Ltd. Buy (bullish), based on 16 analysts. Average price target: US$22.75.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 October 2022
Declarations46 total
15,900 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006955:0
2,900 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006961:0
2,583,658 shares@ US$148.5098.6% of flowCommon SharesSEC:0001562180-22-006953:0
11,653 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006949:0
3,025,001 shares@ US$148.5099.8% of flowCommon SharesSEC:0001562180-22-006964:0
5,068 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006956:0
6,177 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006959:0
92,050 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006963:0
22,362 shares@ US$148.5083.5% of flowCommon SharesSEC:0001562180-22-006950:0
11,090 shares@ US$148.5093.1% of flowCommon SharesSEC:0001562180-22-006951:0
4,292 shares@ US$148.5039.3% of flowCommon SharesSEC:0001562180-22-006952:0
14,226 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006962:0
10,640 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006958:0
38,000 shares@ US$148.04411.4% of flowCommon StockSEC:0001562180-22-006259:0
Canonical exit: 17 Nov 2022 (T+90)
2,250 shares@ US$53.760.0087% mcap11.4% of flowCommon SharesSEC:0001562180-22-004014:0
2,464 shares@ US$67.82740.011% mcap3.3% of flowCommon SharesSEC:0001562180-22-001435:0
11,706 shares@ US$64.42210.051% mcap14.9% of flowCommon SharesSEC:0001562180-22-001434:0
3,750 shares@ US$53.760.013% mcap17.7% of flowCommon SharesSEC:0001562180-22-000587:0
1,875 shares0Common SharesSEC:0001562180-22-000436:0
937 shares0Common SharesSEC:0001562180-22-000439:0
1,000 shares0Common SharesSEC:0001562180-22-000440:0
3,750 shares0Common SharesSEC:0001562180-22-000352:0
3,750 shares0Common SharesSEC:0001562180-22-000353:0
1,250 shares0Common SharesSEC:0001562180-22-000357:0
5,000 shares0Common SharesSEC:0001562180-22-000351:0
25 of 46 declarations
About Biohaven Pharmaceutical Holding Co Ltd.
Biohaven Ltd. is a U.S.-listed biopharmaceutical company traded on the NYSE under the ticker BHVN. Its headquarters are in New Haven, Connecticut, placing it in a major U.S. life-sciences hub with close historical ties to Yale and the Northeast biotech ecosystem. The company as it exists today is relatively recent: it was formed following a spin-off completed in October 2022 from the former Biohaven Pharmaceutical Holding Company Ltd. Biohaven describes itself as a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for both rare and common diseases, with an emphasis on platform-driven innovation rather than a large portfolio of established marketed drugs.([ir.biohaven.com](https://ir.biohaven.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-fourth-0?utm_source=openai)) The company’s business model is centered on multiple R&D franchises, including migraine, targeted extracellular protein degraders, antibody-drug conjugates (ADCs), and other early- to mid-stage assets. Biohaven initially built market recognition in migraine through Nurtec ODT (rimegepant) and Zavzpret (zavegepant), which helped establish its clinical and commercial credibility in a highly competitive therapeutic area. Today, management emphasizes a broader platform strategy, especially its MoDE and TRAP degrader technologies, which are designed to selectively degrade extracellular proteins, alongside next-generation ADC efforts. This portfolio expansion broadens Biohaven’s potential beyond migraine into immunology, inflammation, rare disease, and selected neuroscience opportunities.([biohaven.com](https://www.biohaven.com/?utm_source=openai)) From a competitive standpoint, Biohaven remains a classic clinical biotech story: high upside, but with meaningful dependence on trial execution, regulatory outcomes, and capital allocation. Its profile is that of a research-intensive company whose valuation is driven by pipeline quality and data readouts rather than near-term earnings power. Recent company updates indicate that in 2025 Biohaven restructured priorities to reduce direct R&D spending and concentrate resources on the most attractive programs. Among the latest notable developments, Biohaven reported quarterly results and business updates in March and May 2026, including progress on BHV-1530, a first-in-class FGFR3-directed ADC, and further advancement of its proprietary degrader platform. The company also points to collaboration activity, which may help share scientific and development risk. For investors, BHVN represents a typical U.S. biotech opportunity: substantial long-term optionality, but limited visibility and high sensitivity to clinical and regulatory catalysts.([ir.biohaven.com](https://ir.biohaven.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-first-quarter?utm_source=openai))
